Adalimumab in Severe and Acute Sciatica

Sponsor
University Hospital, Geneva
Study ID
NCT00470509
Phase
PHASE2
Status
Completed

Conditions

  • Sciatica

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Adalimumab — DRUG
    2 subcutaneous injections on day 0 and 7
  • Placebos — DRUG
    2 subcutaneous injections on day 0 and 7

Study Details

The purpose of this study is to determine whether adalimumab (a TNF-alpha inhibitor) is effective in the treatment of severe and acute sciatica.

Key Dates

Start date
May 31, 2005
Status verified
Apr 2019
Primary completion
Jan 31, 2008
Completion
Jun 30, 2008

Study Design

Enrollment
61 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Adalimumab
    adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
  • Placebo Comparator: Placebo
    2 placebo injections on day 0 and 7

Primary Outcome Measure

Leg pain [ Time Frame: 6 months ]

Related Studies